Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone

Abstract

BACKGROUND Use of azathioprine (AZA) for inflammatory bowel disease is limited by side effects or poor efficacy. Combining low-dose azathioprine with allopurinol (LDAA) bypasses side effects, improves efficacy, and may be appropriate as first-line therapy. We test the hypothesis that standard-dose azathioprine (AZA) and LDAA treatments work by similar… (More)
DOI: 10.1097/MIB.0000000000001131

Topics

7 Figures and Tables

Cite this paper

@inproceedings{Coulthard2017AzathioprineWA, title={Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone}, author={Sally A. Coulthard and Phil H Berry and Sarah McGarrity and Simon McLaughlin and Azhar Ansari and Christopher P. F. Redfern}, booktitle={Inflammatory bowel diseases}, year={2017} }